CW
HRTX icon

CreativeOne Wealth’s Heron Therapeutics HRTX Stock Holding History

CreativeOne Wealth’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,846
Closed -$23.6K – 1093
2024
Q3 		$23.6K Buy
11,846
+138
+1% +$330 ﹤0.01% 940
2024
Q2 		$41K Buy
11,708
+866
+8% +$2.66K ﹤0.01% 757
2024
Q1 		$30K Sell
10,842
-1,863
-15% -$4.68K ﹤0.01% 868
2023
Q4 		$22K Buy
12,705
+1,271
+11% +$1.4K ﹤0.01% 618
2023
Q3 		$12K Hold
11,434
– – ﹤0.01% 566
2023
Q2 		$13K Sell
11,434
-30
-0.3% -$54 ﹤0.01% 826
2023
Q1 		$17K Sell
11,464
-300
-3% -$751 ﹤0.01% 788
2022
Q4 		$29K Buy
11,764
+20
+0.2% +$64 ﹤0.01% 729
2022
Q3 		$50K Hold
11,744
– – ﹤0.01% 688
2022
Q2 		$33K Buy
11,744
+1,450
+14% +$5.82K ﹤0.01% 709
2022
Q1 		$59K Buy
10,294
+250
+2% +$1.83K ﹤0.01% 726
2021
Q4 		$92K Buy
+10,044
New +$103K ﹤0.01% 739

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CreativeOne Wealth's HRTX Position: Q4 2024 in Review

CreativeOne Wealth sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 11,846 shares — an estimated $23.6K sold.

CreativeOne Wealth first reported a position in HRTX in Q4 2021 and held it in 12 quarters. The position peaked at $92K in Q4 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • CreativeOne Wealth reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CreativeOne Wealth sold 11,846 Heron Therapeutics shares in Q4 2024, an estimated $23.6K.
  • CreativeOne Wealth first reported a position in Heron Therapeutics in Q4 2021 and held it in 12 quarters.
  • CreativeOne Wealth's Heron Therapeutics position peaked at $92K in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on CreativeOne Wealth's 13F filing for Q4 2024, filed 13 Feb 2025.